Shares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844